Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma

✍ Scribed by M. V. Kopp; E. Hamelmann; S. Zielen; W. Kamin; K.-C. Bergmann; C. Sieder; S. Stenglein; S. Seyfried; U. Wahn; for the DUAL study group

• Book ID: 108688363
• Publisher: John Wiley and Sons
• Year: 2009
• Tongue: English
• Weight: 184 KB
• Volume: 39
• Category: Article
• ISSN: 0954-7894
• DOI: 10.1111/j.1365-2222.2008.03121.x